Introduction
Adult treatment panel (ATP) guidelines of National Cholesterol Education Programme (NCEP) 2001 1 established the importance of lowering 'low density lipoproteins' (LDL) cholesterol as the mainstay of treatment of atherosclerotic cardiovascular disease (ASCVD). Statins and nonstatins were titrated to a LDLc goal of 60-80 mg/dl. The ideal principle 'Treat to target' was recommended and optimal LDLc level was considered 50-70 mg/dl (<70 mg/dl). 2 Cholesterol Treatment Trialist Collaboration 3 showed that benefit of statin therapy was tied to absolute ASCVD risk reduction and absolute lowering of LDLc levels. Statins are the most effective and validated therapy to lower LDLc by inhibiting cholesterol synthesis by inhibiting HMG-CoA reductase. 4 
Objective 4.

Results
Cholesterol treatment guidelines (CTG
Monitoring of lipid profile during statin therapy
2013 ACC/AHA guidelines on cholesterol management have not recommended specific LDL (c) and non-HDL (c) targets when the patients has been put on high intensive statin therapy (e.g. atorvastatin 80 mg/day or rosuvastatin 40 mg/ day). This shift in the management has become a subject of major controversy. [10] [11] [12] Many advanced countries follow their own guidelines. [7] [8] [9] Even in our country, recent consensus on management of dyslipidemia in Indian subjects have raised observations regarding ACC/AHA guidelines and their relevance in Indian population. 13 High intensity statin therapy is intended to reduced CV risk by >50% which is related to lowering of LDL(c) levels. 3 This is consistent with the recent standards of medical care in diabetes. 14 Hence it may be justified to monitor LDL (c) in order to judge CV Risk reduction. In addition, individual response and tolerability to high intensity statin therapy may vary considerably. South Asians including Indians respond differently compared to their Western counterparts. 15 Although statins are pretty safe drugs but instance of muscle toxicity has been reported in 10-20% cases. Severe myositis with raised serum creatine phosphokinase (CPK) and even rhabdomyolysis with myoglobinuria and raised serum creatinine have been described. Under such circumstance of statin intolerance, alternative lipids lowering drugs are required. PROVE IT, TIMI-22 Trial has provided uncontroversial data to prove the beneficial effects of intensive lipid lowering in acute coronary syndrome and diabetes. 16 However about 20% 
IMPROVED REDUCTION OF OUTCOME VYTORIN EFFICACY INTERNATIONAL TRIAL (IMPROVE IT)
19 studied the efficacy of 'ezetimibe' when added to simvastatin. A total of 18444 patients were randomized at 1158 centers in 39 countries; 9067 were given ezetimibe (10 mg) plus simvastatin (40 mg) while 9077 received simvastatin (40 mg) orally. Baseline clinical and biochemical data were almost identical in the two groups and their mean basal LDLc was 95 mg/dl. After one year of therapy, mean LDLc levels in the two groups were 53.7 mg/dl and 69.7 mg/dl respectively. However the primary end point of CV death, myocardial infarction (MI) or unstable angina (UA) or stroke was significantly lower in ezetimibe PLUS simvastatin group (20.4%) compared with simvastatin alone group (22.2%). IMPROVE IT trial concluded that addition of ezetimibe produced lower LDLc and better CV end results than simvastatin alone. Trial also confirmed the earlier notion about LDLc ''the lower the better''.
Recently approved therapies for homozygous familial hypercholesterolemia (HOFH)
Microsomal triglyceride transfer protein (MTTP) inhibitor 'LOMITAPIDE' (Aegerion Pharmaceuticals, USA) and Apoprotein B (Apo B) antisense oligonucleotide (ASO) 'Mipomersen' (Kynamro Genzyme Corporation, USA) have been recently approved by FDA, for restricted use in HOFM through Risk Evaluation and Mitigation Strategy (REMS) since their safety has not been fully evaluated. Lomitapide but not Mipomersen has been approved by European Medicines Agency for HOFH only. Both drugs are prohibitively costly.
Microsomal triglyceride transfer protein (MTTP) inhibitor 'Lomitapide' inhibits the production of Apo-B resulting in diminished secretion of chylomicrons, VLDL and LDL. The efficacy and safety of Lomitapide has been studied in 29 HOFH patients. 20 The drug was given in the increasing doses from 5 to 60 mg/day for 26 weeks and followed till 78 weeks for safety assessment. 23 patients completed 78 weeks of study with a median dose of 40 mg/day along with statin and nonstatin drugs. Mean LDLc diminished from baseline of 336 mg/dl to 166 mg/dl at 26 weeks but increased to 208 mg/dl at 78 weeks. The side effects were nausea, diarrhea and raised transaminases. Antisense oligonucleotide (ASO) 'mipomersen' binds with RNA of Apo-B in the liver and reduces the synthesis of all lipoproteins including LDLc. Mipomersen was studied in 158 hypercholesterolemic patients with baseline LDLc >100 mg/dl, who were receiving maximally tolerated lipid lowering therapy. 21 Patients received weekly subcutaneous mipomersen 200 mg (n = 105) or placebo (n = 52) for 26 weeks with a 24 weeks follow up; 60 on mipomersen and 44 on placebo completed 50 weeks. Mean baseline LDLc levels were 122.6 mg/ dl and 122.7 mg/dl in the mipomersen and placebo groups respectively. Mipomersen reduced LDLc by 36.9% compared with 4.5% in placebo group. Side effects with mipomersen were skin reaction at injection site (78%), flu like symptoms (34%) and raised transaminases (10%). Of 54 patients who discontinued, 45 were in the mipomersen group and 9 in placebo group. Hence, mipomersen appears toxic for routine use. Both above drugs not recommended for nonfamilial hypercholesterolemia.
6.
Future therapy -PCSK 9 inhibitors
Proprotein convertase subtilisin/Kexin 9 (PCSK-9) is an enzyme discovered in 2003. It is encoded by PCSK-9 gene. It is chiefly expressed in the liver and intestines. PCSK-9 is an inhibitor of LDL receptors (LDL R) which is a preferential pathway through which LDLc is normally cleared from the blood. LDLc gets bound to LDL (R) on the surface of liver cells and then internalized into the liver cells where LDL is further metabolized while LDL(R) returns back to the surface of liver cells for further interaction the LDLc. This process continues for several cycles. PCSK 9 binds with LDL(R) on the surface of liver cells and promotes degradation of LDL(R) in the liver cells by the lysozyme pathway and prevents its recycling back to the liver cell surface. PCSK 9 inhibitors inhibit the binding of PCSK 9 with LDL(R) and prevent the degradation of LDL(R) which is thus available to mop more LDLc for metabolism. It was observed that a rare 'gain of function' by gene mutation of PCSK 9 leads to severe elevation of LDLc and premature ASCVD whereas rare 'loss of function' by gene mutation of PCSK 9 reduces LDLc and decreases the incidence of ASCVD. 22 This research provided impetus and rational to develop PCSK 9 inhibitors to lower LDLc. Elevated serum levels of PCSK 9 have been reported during statin therapy and in familial hypercholesterolemia. Elevated plasma PCKS 9 levels is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of LD(R) defects. 23 [27] [28] [29] showed that evolocumab is able to reduce
LDLc from 40 to 80%, apolipoprotein B from 30 to 59% and lipoprotein A from 18 to 36%. The reduction of LDLc is on monotherapy as well as when given with statins and the reduction is dose dependent. There were few side effects limited to nasopharyngitis, local skin reaction at injection site and arthralgia. MANDEL-2 30 Phase III clinical trial was anti-PCSK-9 monotherapy for hypercholesterolemia in 614 patients who were randomly assigned to Evolocumab (n = 306), placebo (n-155) and ezetimibe (n = 154). Evolocumab was given 140 mg once in two weeks (n = 153) or 420 mg once a month (n = 163). LDLc decreased from baseline on average by 56% in comparison with 17.8% with ezetimibe and <1% on placebo. Serious side effects encountered with evolocumab were acute pancreatitis (one patient) and raised transaminases (one patient). GAUSS2 randomized placebo controlled trial 31 
7.
Odyssey FH1 and FH2
Familial hypercholesterolemia is due to genetic mutation of gene resulting in either absence or defective LDL(R). There is excessive cumulative load of LDLc leading to premature ASCVD. In homozygous familial hypercholesterolemia (HOFH), LDL(R) is either totally absent or grossly defective due to two identical mutations while in heterozygous familial hypercholesterolemia (HeFH), LDL(R) is defective but not totally absent due to single mutation. In HOFH, LDLc is usually markedly raised (>500 mg/dl), while in HeFH > 190-400 mg/ dl. The ASCVD outcome is seriously affected due to raised LDLc. Alirocumab inhibits PCSK 9 and preserves LDL(R) and reduces LDLc in HeFH. In HOFH, alirocumab may be helpful if LDL(R) is only defective but not absent. Odyssey FH1 and FH2 are being conducted simultaneously in N America, Europe and S Africa and includes 735 HeFH patients. Alirocumab is given in dose of 75 mg once in two week. 40% required upgradation of dose to alirocumab to 150 mg once in two weeks. LDLc reduction with alirocumab has been significant (49%) and sustained.
Odyssey Combo Trial includes 720 hypercholesterolemia patients with high CV risk and inadequately controlled by maximally tolerated statins plus ezetimibe. 479 of them were given alirocumab (either 75 or 150 mg once in two weeks), while the remaining 241 continued on statin plus ezetimibe. Results are awaited.
Odyssey i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 4 1 9 -4 2 4
8.
Conclusion
Today PCSK 9 inhibition is a new concept in the management of cholesterol. Till now, the emphasis was either reduced cholesterol intake or reduced cholesterol synthesis. PCSK 9 inhibitors inhibit the binding of PCSK 9 enzyme with LDL receptors and prevent degradation of LDL receptor. Thus LDL receptor is available to bind with LDL(c) and its disposal by hepatocytes.
Administration of PCSK 9 inhibitors by subcutaneous route may cause skin discomfort and local reaction. Trials undertaken so far have not reported any major side effects during the study periods varying 6-18months. Further ongoing research on the development and refinement of PCSK 9 inhibitors may culminate in the synthesis of safer and more acceptable analogs. Since the drugs are yet not marketed, their cost is not known. Long term safety and cost effectiveness are important factors to decide the future of this innovative treatment. The research for new acceptable analogs must continue if we desire purposeful results.
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